<DOC>
	<DOCNO>NCT02939820</DOCNO>
	<brief_summary>The purpose study provide expand access patisiran patient hereditary transthyretin-mediated amyloidosis ( hATTR ) .</brief_summary>
	<brief_title>Expanded Access Protocol Patisiran Patients With Hereditary ATTR Amyloidosis ( hATTR )</brief_title>
	<detailed_description>Choosing participate expand access program important personal decision . Talk doctor family member friends decide join research study . To learn study , doctor may contact study research staff use Contacts provide . For general information , see link provide More Information .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<mesh_term>Amyloidosis , Familial</mesh_term>
	<criteria>Male female great equal 18 year age Have diagnosis hATTR Meet Karnofsky performance status Polyneuropathy Disability ( PND ) score requirement Have adequate complete blood count , liver function test coagulation test Participated interventional hATTR amyloidosis clinical trial within last 24 month know receive active hATTR amyloidosis investigational therapy Are currently eligible participate currently enrol ongoing interventional hATTR amyloidosis clinical trial Have inadequate cardiac function Known primary amyloidosis ( AL amyloidosis ) leptomeningeal amyloidosis Have know serious comorbidities consider unfit program investigator Prior plan liver heart transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathies</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>